Summary
- Novartis Shares Update on VIBRANT-HD
- HDSA Research Webinar Next Week: Ask the Scientists...Anything!
- Now Accepting Applications For 2023 Berman-Topper and Donald A. King Research Fellowships
Novartis Shares Update on VIBRANT-HD
Today Novartis shared that they will end development of branaplam for HD. This difficult news comes after dosing of branaplam in the Phase 2b VIBRANT-HD study was suspended in August of this year due to signs of injury to nerves outside of the brain, called peripheral neuropathy. Although branaplam was found to lower mutant huntingtin, these negative side effects make it unlikely that the drug will be safe at doses that would offer therapeutic benefit.
Despite this disappointing end to VIBRANT-HD, Novartis remains committed to learning as much as possible about the effects of branaplam and making that knowledge available to the entirety of the HD community for the benefit of future drug development endeavors. To read the full community letter, click here.
HDSA Research Webinar Next Week: Ask the Scientists…Anything!
On Thursday, December 15th at 1PM ET, HDSA will be joined by expert HD scientists and HDBuzz editors, Drs. Jeff Carroll and Rachel Harding, to answer your questions about HD research, reflect on another eventful year of HD science, and celebrate all we have to look forward to in 2023. Register to join HDSA’s last research webinar of the year by clicking here.
Now Accepting Applications For 2023 Berman-Topper and Donald A. King Research Fellowships
On December 6th, HDSA launched applications for the 2023 cycles of its competitive Berman-Topper Family HD Career Development Fellowship and Donald A. King Summer Research Fellowship. To learn more about these exciting opportunities and how to apply, visit the Berman-Topper Fellowship and Donald A. King Fellowship pages on HDSA’s website.
